Vir Biotechnology awarded up to $1B BARDA contract for influenza and pandemic preparedness

Vir Biotechnology, Inc.

BARDA to invest ~$55M initially for VIR-2482 (influenza prophylactic mAb) development through Jan 2026.
Phase 2 trial of VIR-2482 expected to start H2 2022; initial data anticipated mid-2023.
Potential total investment up to $1B if BARDA exercises up to 12 options for additional candidates.
Contract supports development of up to 10 emerging infectious disease or medical countermeasure candidates.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.